{'fraction_non_alphanumeric': 0.03866432337434095, 'fraction_numerical': 0.03163444639718805, 'mean_word_length': 4.816326530612245, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias

Aclarubicin (ACM), 25 mg/m2 daily for seven days, was administered as induction therapy to 40 patients with relapsing or refractory acute leukaemias. Eight complete (CR) and 1 partial (PR) remission were achieved in 29 evaluable AML patients (31%). A high CR rate was induced in patients treated at first relapse (6 out of 12 patients). A small proportion of AML resistant to daunorubicin or doxorubicin responded to ACM (3 out of 17 patients). Median remission duration was 5.5 months.